High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma
Cancers · 30.03.2023 · 15 (7) · 2071
DOI: 10.3390/cancers15072071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 30.03.2023. Verfasst von Sebastian Blatt und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Medical Centre Mainz.
Abstract (Originalsprache)
Improved serological biomarkers are needed for the early detection, risk stratification and treatment surveillance of patients with oral squamous cell carcinoma (OSCC). We performed an exploratory study using advanced, highly specific, DNA-aptamer-based serum proteomics (SOMAscan, 1305-plex) to identify distinct proteomic changes in patients with OSCC pre- vs. post-resection and compared to healthy controls. A total of 63 significantly differentially expressed serum proteins (each p < 0.05) were found that could discriminate between OSCC and healthy controls with 100% accuracy. Furthermore, 121 proteins were detected that were significantly altered between pre- and post-resection sera, and 12 OSCC-associated proteins reversed to levels equivalent to healthy controls after resection. Of these, 6 were increased and 6 were decreased relative to healthy controls, highlighting the potential relevance of these proteins as OSCC tumor markers. Pathway analyses revealed potential pathophysiological mechanisms associated with OSCC. Hence, quantitative proteome analysis using SOMAscan technology is promising and may aid in the development of defined serum marker assays to predict tumor occurrence, progression and recurrence in OSCC, and to guide personalized therapies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, University Medical Center, 55131 Mainz, Germany.
- Institute of Translational Immunology and Research Center for Immune Therapy (FZI), University Medical Center of the Johannes Gutenberg-University, 55131 Mainz, Germany.
- Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Division of Interdisciplinary Medicine and Biotechnology, Beth Israel Deaconess Medical Center, Harvard Medical Schoo…
- Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
ORCID-Profile: Peer W Kämmerer, Daniel G E Thiem, Bilal Al-Nawas, Towia A Libermann
Förderung
- University Medical Centre Mainz
Zitieren
APA
Blatt, S., Kämmerer, P. W., Krüger, M., Surabattula, R., Thiem, D. G. E., Dillon, S. T., Al-Nawas, B., Libermann, T. A., & Schuppan, D. (2023). High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma. Cancers, 15(7), 2071. https://doi.org/10.3390/cancers15072071
Vancouver
Blatt S, Kämmerer PW, Krüger M, Surabattula R, Thiem DGE, Dillon ST, et al. High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma. Cancers. 2023;15(7):2071. doi:10.3390/cancers15072071
BibTeX
@article{Blatt2023,
author = {Blatt, Sebastian and Kämmerer, Peer W and Krüger, Maximilian and Surabattula, Rambabu and Thiem, Daniel G E and Dillon, Simon T and Al-Nawas, Bilal and Libermann, Towia A and Schuppan, Detlef},
title = {High-Multiplex Aptamer-Based Serum Proteomics to Identify Candidate Serum Biomarkers of Oral Squamous Cell Carcinoma},
journal = {Cancers},
year = {2023},
volume = {15},
number = {7},
pages = {2071},
doi = {10.3390/cancers15072071}
}
EUVIMED